1,045
Participants
Start Date
October 31, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
TAK-442
TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
TAK-442
TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
TAK-442
TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
TAK-442
TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
TAK-442
TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
TAK-442
TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
Enoxaparin
Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
Birmingham
Tuscaloosa
Phoenix
Little Rock
Bakersfield
Fountain Valley
Long Beach
Montclair
Oceanside
Vista
Yuba City
Aurora
Centennial
Denver
Bay Pines
Clearwater
DeLand
Gulf Breeze
Hollywood
Pinellas Park
Tamarac
Atlanta
Boise
Meridian
Springfield
Towson
Charlotte
Greensboro
Cincinnati
Tulsa
Altoona
Johnstown
Charleston
Dallas
Grapenne
Lubbock
San Antonio
Spokane
Edmonton
Red Deer
Kelowna
Winnipeg
Fredericton
Saint John
Dartmouth
Ajax
Burlington
Cambridge
Chatham
Greater Sudbury
Guelph
Kitchener
Newmarket
Niagra Falls
Oakville
Oshawa
Ottawa
Saint Catherines
Sarnia
Scarborough Village
Thunder Bay
Windsor
Montreal
Charlottetown
Lead Sponsor
Takeda
INDUSTRY